Sign in
Taking people in United StatesNo phase

Follows pregnant women with migraine who take erenumab

Tracks babies born to women with migraine who took erenumab during pregnancy.

Key facts

Who runs it
Amgen
Where
Durham, United StatesSee the site
Trial code
Registry title
Aimovig Pregnancy Exposure Registry
Status
Recruiting
People taking part
2,842 people, planned
Started
27 Jan 2021
Expected to end
28 Oct 2027
Type of study
Observational, 3 groups
Treatments tested
  • erenumab-aooe
Record updated
4 November 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for pregnant women aged 18 or older with a confirmed migraine diagnosis. It follows birth outcomes in women who did or did not take erenumab-aooe.

Age
18 years or older (up to 99 years).
Sex
Women only.
Disease stage
Confirmed clinical diagnosis of migraine. The pregnancy outcome must not be known yet.
Earlier treatment
The trial looks at women who took erenumab-aooe before or during pregnancy, and women who did not. Women who took other medicines that target the CGRP pathway (CGRP monoclonal antibody or gepants) from 5 half-lives before the last menstrual period through the end of pregnancy cannot join.

Main reasons for not taking part

  • Taking part in another investigational device or drug study
  • Taking an investigational medicine now, or within 3 months before the last menstrual period or during pregnancy
  • Taking CGRP-targeting medicines (CGRP monoclonal antibody or gepants) from 5 half-lives before the last menstrual period through the end of pregnancy

This trial only enrols pregnant participants. The registry sentence this rests on: Currently pregnant

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Age 18 years or older (at time of signing the informed consent)
  • Currently pregnant
  • The outcome of the pregnancy must not be known
  • Confirmed clinical diagnosis of migraine

Who cannot take part

  • Women currently participating in another investigational device or investigational drug study, currently taking an investigational medicinal product, or having taken an investigational product within 3 months prior to last menstrual period (LMP) or during pregnancy. Other investigational procedures while participating in this study are excluded
  • Women exposed to any medications that target the calcitonin gene-related peptide (CGRP) pathway (ie, CGRP monoclonal antibody [mAb] or gepants) in the period from 5 half-lives prior to LMP through the end of pregnancy

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 99 years old?

Where in United States

  • Durham, North CarolinaHospital not named in the registryTaking people

About the trial

What the trial wants to find out

The primary objective of this study is to estimate the proportion of major congenital malformations in infants of women with migraine exposed to erenumab-aooe during pregnancy compared to infants of women with migraine unexposed to erenumeb-aooe.

The 3 groups in the trial

  • Erenumab-aooe-exposed

    Pregnant women with confirmed migraine who received erenumab-aooe before or during pregnancy will qualify to be included in the cohort. Dosing and treatment duration of erenumab-aooe as part of this observational study is at the discretion of the healthcare provider (HCP) in accordance with local clinical practice and local labeling.

    Treatment: erenumab-aooe

  • Erenumab-aooe-unexposed (Internal Comparator)

    Pregnant women with clinically confirmed migraine who were not exposed to erenumab-aooe before or during pregnancy will be included in the internal comparator cohort.

  • Women Without Migraine (External Comparator)

    Pregnant woman without migraine will be included in this cohort as external comparator. The Metropolitan Atlanta Congenital Defects Program (MACDP) birth defects classification system will be used to characterize major and minor congenital malformations for this study.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
GENESIS: AIMOVIG® Pregnancy Exposure Registry
Plain-language title
Follows pregnant women with migraine who take erenumabGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06150781, who can take part
Record updated
4 November 2025